1,721,066 research outputs found
Topography, morphology, and etiology of lymphocytic gastritis: a focus on celiac disease
No full textControversial Contribution of Th17/IL-17 Toward the Immune Response in Intestinal Fibrosis
No full textIntestinal fibrosis is a common outcome of inflammatory bowel diseases (IBDs), becoming clinically apparent in 40% of patients with Crohn's disease and 5% of those with ulcerative colitis. Effective pharmacological treatments aimed at controlling or reversing fibrosis progression are unavailable. Fibrosis is characterized by an excessive local accumulation of extracellular matrix proteins (mainly collagen), as a result of their increased production by activated myofibroblasts and/or their reduced degradation by specific matrix metalloproteinases. Initiation and progression of fibrosis are modulated by several pro- and anti-fibrogenic molecules. In recent years, the cytokine interleukin-17 (IL-17) has been integrated into the pathogenesis of fibrosis, although its precise contribution to IBD, and especially to its related intestinal fibrosis, remains controversial. Several data suggest both a pro-inflammatory and pro-fibrotic action and a protective function of the Th17/IL-17 immune response. A recent study has demonstrated that the treatment with anti-IL-17 antibody significantly alleviated 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colorectal fibrosis in mice by down-regulating the expression of collagen 3 and several pro-fibrogenic cytokines. Here, we describe and discuss the possible involvement of the Th17/IL-17 immune response in the initiation ad progression of intestinal fibrosis
Efficacia di un nuovo preparato di olio di pesce sulla recidiva del Morbo di Crohn. Giornale di Gastroenterologia 1996;1:158-162
No full textL’intestino nei pazienti critici. La barriera mucosa intestinale e le sue alterazioni (prima parte). Giornale di Gastroenterologia 1998; 3: 70-103
No full text
Current management of severe ulcerative colitis.
No full textApproximately 15% of patients with ulcerative colitis develop an acute attack of
severe colitis, and 30% of these patients require colectomy. Severe ulcerative
colitis is therefore considered a medical emergency, the management of which
requires close collaboration between gastroenterologists and surgeons. The
mortality rate for patients with severe ulcerative colitis is now <1% in
specialist centers, but it was high before intravenous steroid therapy and early
surgery were introduced; indeed, mortality is still high in nonspecialized
centers. As colectomy severely affects quality of life, therapy with intravenous
ciclosporin and, more recently, infliximab has been introduced to try to avoid
the need for surgery. Ciclosporin induces short-term remission, but the long-term
benefit remains unsatisfactory as colectomy is often only delayed. A significant
short-term reduction in the colectomy rate has, however, been observed after
infliximab treatment. The use of infliximab versus ciclosporin in patients with
severe ulcerative colitis remains to be defined. The timing of surgery remains a
cardinal decision in the management of severe ulcerative colitis; increased
morbidity resulting from prolonged ineffective medical treatment and, therefore,
a delay in surgical treatment should be avoided
Diarrea Cronica In: Disturbi cronici intestinali, E.Corazziari Ed., Milano, Messaggi, 2003:127-135
No full textChronic Diarrhoea. In: Chronic Gastrointestinal Disorders, E.Corazziari Ed, Milano, Messaggi, 1999:295-302
No full textRecidive stenosanti ricorrenti nel morbo di Crohn. Giornale di Gastroenterologia, 1999, 4: 150-155
No full text- …
